Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 human coronavirus <i>in vitro</i>

Nathan E. Stone(Northern Arizona University), Christopher T. French(Northern Arizona University), Ashley Jones(Northern Arizona University), Sierra A. Jaramillo(Northern Arizona University), Adam J. Vazquez(Northern Arizona University), Lora M. Versluis(Northern Arizona University), Haley E. Nunnally(Northern Arizona University), Erik W. Settles(Northern Arizona University), Roxanne Nottingham(Northern Arizona University), Paul Keim(Northern Arizona University), Steen Knudsen(MC2 Therapeutics (Denmark)), Jason W. Sahl(Northern Arizona University), David M. Wagner(Northern Arizona University), Madison Martz(Northern Arizona University), Marlee O. Raniere(Northern Arizona University), Katherine E. Zarn(Northern Arizona University)
bioRxiv (Cold Spring Harbor Laboratory)
November 12, 2020
Cited by 0


Related Papers